Aravive, Inc. (ARAV) shares are gaining more than 8 percent on Thursday morning trade after reporting positive initial reports from Phase 1b and Phase 1b/2 study of AVB-500 in combination with Cabozantinib in Clear Cell Renal Carcinoma. The clinical-stage oncology company said it plans to expand the dosing of 15mg/kg of AVB-500 to an additional three patients to determine the potential of initiating the Phase 2 portion with this dose. The Phase 1b dose escalation study will enroll up to 18 patients in 15 mg/kg, 20 mg/kg and 25 mg/kg dosing to evaluate tolerability and pharmacokinetics.
Currently, shares are at $5.77, up 8.46 percent from the previous close of $5.32 on a volume of 19,104,845. The shares have traded in a range of $4.27-$14.94 on average volume of 155,259.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.